- Home
- GOSS vs YMAB Comparison
GOSS vs YMAB Comparison
Compare GOSS & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- YMAB
- Stock Information
- Founded
- GOSS 2015
- YMAB 2015
- Country
- GOSS United States
- YMAB United States
- Employees
- GOSS N/A
- YMAB N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- GOSS Health Care
- YMAB Health Care
- Exchange
- GOSS Nasdaq
- YMAB Nasdaq
- Market Cap
- GOSS 347.8M
- YMAB 386.7M
- IPO Year
- GOSS 2019
- YMAB 2018
- Fundamental
- Price
- GOSS $1.96
- YMAB $8.52
- Analyst Decision
- GOSS Strong Buy
- YMAB Buy
- Analyst Count
- GOSS 4
- YMAB 11
- Target Price
- GOSS $8.50
- YMAB $15.02
- AVG Volume (30 Days)
- GOSS 3.2M
- YMAB 1.7M
- Earning Date
- GOSS 08-05-2025
- YMAB 08-08-2025
- Dividend Yield
- GOSS N/A
- YMAB N/A
- EPS Growth
- GOSS N/A
- YMAB N/A
- EPS
- GOSS N/A
- YMAB N/A
- Revenue
- GOSS $40,237,000.00
- YMAB $85,385,000.00
- Revenue This Year
- GOSS N/A
- YMAB N/A
- Revenue Next Year
- GOSS $63.97
- YMAB $15.23
- P/E Ratio
- GOSS N/A
- YMAB N/A
- Revenue Growth
- GOSS N/A
- YMAB N/A
- 52 Week Low
- GOSS $0.66
- YMAB $3.55
- 52 Week High
- GOSS $2.23
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- GOSS 58.35
- YMAB 81.55
- Support Level
- GOSS $1.67
- YMAB $8.50
- Resistance Level
- GOSS $2.00
- YMAB $8.53
- Average True Range (ATR)
- GOSS 0.17
- YMAB 0.15
- MACD
- GOSS -0.02
- YMAB 0.25
- Stochastic Oscillator
- GOSS 52.21
- YMAB 99.54
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.